- Home
- RTO vs MRNA Comparison
RTO vs MRNA Comparison
Compare RTO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RTO
- MRNA
- Stock Information
- Founded
- RTO 1925
- MRNA 2010
- Country
- RTO United Kingdom
- MRNA United States
- Employees
- RTO N/A
- MRNA N/A
- Industry
- RTO Business Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RTO Consumer Discretionary
- MRNA Health Care
- Exchange
- RTO Nasdaq
- MRNA Nasdaq
- Market Cap
- RTO 12.2B
- MRNA 13.4B
- IPO Year
- RTO N/A
- MRNA 2018
- Fundamental
- Price
- RTO $23.73
- MRNA $27.61
- Analyst Decision
- RTO Hold
- MRNA Hold
- Analyst Count
- RTO 1
- MRNA 20
- Target Price
- RTO N/A
- MRNA $46.76
- AVG Volume (30 Days)
- RTO 877.2K
- MRNA 9.0M
- Earning Date
- RTO 08-05-2025
- MRNA 08-01-2025
- Dividend Yield
- RTO 2.22%
- MRNA N/A
- EPS Growth
- RTO N/A
- MRNA N/A
- EPS
- RTO 0.13
- MRNA N/A
- Revenue
- RTO $7,581,860,530.00
- MRNA $3,078,000,000.00
- Revenue This Year
- RTO $15.25
- MRNA N/A
- Revenue Next Year
- RTO $4.21
- MRNA $10.04
- P/E Ratio
- RTO $35.59
- MRNA N/A
- Revenue Growth
- RTO 1.14
- MRNA N/A
- 52 Week Low
- RTO $19.60
- MRNA $23.15
- 52 Week High
- RTO $34.07
- MRNA $102.90
- Technical
- Relative Strength Index (RSI)
- RTO 48.91
- MRNA 36.94
- Support Level
- RTO $22.77
- MRNA $33.35
- Resistance Level
- RTO $25.51
- MRNA $34.70
- Average True Range (ATR)
- RTO 0.44
- MRNA 1.47
- MACD
- RTO -0.02
- MRNA -0.66
- Stochastic Oscillator
- RTO 34.78
- MRNA 11.53
About RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest-control and commercial hygiene services, operating in 83 countries. The group also offers a range of specialist route-based services including office and commercial space plant care, property care, and workwear rentals. The group has a diverse client base that includes global food producers, hotel chains, industrial goods businesses, restaurants, and individual residential customers.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.